Serotonin Transporter and Plasma Membrane Monoamine Transporter Are Necessary for the Antidepressant-Like Effects of Ketamine in Mice
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Major depressive disorder is typically treated with selective serotonin reuptake inhibitors (SSRIs), however, SSRIs take approximately six weeks to produce therapeutic effects, if any. Not surprisingly, there has been great interest in findings that low doses of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, produce rapid and long-lasting antidepressant effects. Preclinical studies show that the antidepressant-like effects of ketamine are dependent upon availability of serotonin, and that ketamine increases extracellular serotonin, yet the mechanism by which this occurs is unknown. Here we examined the role of the high-affinity, low-capacity serotonin transporter (SERT), and the plasma membrane monoamine transporter (PMAT), a low-affinity, high-capacity transporter for serotonin, as mechanisms contributing to ketamine’s ability to increase extracellular serotonin and produce antidepressant-like effects. Using high-speed chronoamperometry to measure real-time clearance of serotonin from CA3 region of hippocampus in vivo, we found ketamine robustly inhibited serotonin clearance in wild-type mice, an effect that was lost in mice constitutively lacking SERT or PMAT. As expected, in wild-type mice, ketamine produced antidepressant-like effects in the forced swim test. Mapping onto our neurochemical findings, the antidepressant-like effects of ketamine were lost in mice lacking SERT or PMAT. Future research is needed to understand how constitutive loss of either SERT or PMAT, and compensation that occurs in other systems, is sufficient to void ketamine of its ability to inhibit serotonin clearance and produce antidepressant-like effects. Taken together with existing literature, a critical role for serotonin, and its inhibition of uptake via SERT and PMAT, cannot be ruled out as important contributing factors to ketamine’s antidepressant mechanism of action. Combined with what is already known about ketamine’s action at NMDA receptors, these studies help lead the way to the development of drugs that lack ketamine’s abuse potential but have superior efficacy in treating depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the antidepressant-like effects of ketamine (32 mg/kg i.p.) were absent in mice lacking SERT or plasma membrane monoamine transporter (PMAT) (Bowman et al., 2020).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bowman et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“These behavioral effects corresponded to a reduction in serotonin clearance in the CA3 region of the hippocampus in WT mice but not SERT or PMAT knockout mice.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bowman et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“Currently this is viewed as the primary mechanism underlying ketamine’s antidepressant-like effects in preclinical studies [8,10].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Ketamine triggers intracellular signaling pathways, including eukaryotic elongation factor 2 (eEF2) kinase, resulting in rapid increases in brain derived neurotrophic factor (BDNF) protein translation [8,9].”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 5×
“To gain a better understanding of the relationship between plasma and brain concentrations of ketamine and antidepressant-like effect in rodents, Can and colleagues [20] measured plasma and brain tissue concentrations of ketamine and its metabolites after systemic administration of 10 mg/kg ketamine in mice, a sub-ane…”
BackgroundMethodResultInfluentialKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 2×
“Ketamine at anesthetic doses is reported to increase serotonin, which may be involved in the psychotic-like symptoms occurring during ketamine emergence [58].”
BackgroundThe ascent of mouse: advances in modelling human depression and anxiety
Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198
The spectrum of behaviors influenced by serotonin
Lucki, I. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00139-5 · Cited by 1,158 · cited 1×
“The antidepressant effect of SSRIs is initiated by blockade of the serotonin transporter (SERT) and ensuing increase in extracellular serotonin [11,12].”
BackgroundCryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,119 · cited 1×
“We also looked for climbing behavior, which is routinely recorded during the FST when using rats as it aids in determining if the antidepressant-like actions of a drug are more strongly influenced by serotonergic or noradrenergic and dopaminergic systems; drugs that act to increase serotonin increase swimming, whereas…”
BackgroundThe role of the hippocampus in the pathophysiology of major depression
Campbell, S., & MacQueen, G. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0441 · Cited by 880 · cited 6×
“Like SSRIs, ketamine also causes robust increases in extracellular serotonin in brain regions important in the pathophysiology of mood disorders [13–15].”
BackgroundMethodInfluentialZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Research works printed but not linked: 1
- Daws L.C. Owens W.A. Toney G.M. High-speed chronoamperometry to measure biogenic amine release and uptake in vivo Neurotransmitter Transporters–Investigate Methods Sitte H. Bonisch H. Humana Press Totowa, NJ, USA 2016 53 81
Cited by
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Yoshida, K., Drew, M. R., Kono, A., Mimura, M., Takata, N., & Tanaka, K. F. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-00990-y · Cited by 55
“The suppressive effects of these drugs on vHP activity may be mediated by direct or indirect serotoninmediated inhibition [20, 46], ketamine-mediated NMDA receptor blockade [37, 40], or ketamine-mediated serotonin uptake inhibition [47]; however, more detailed investigations will be necessary to explain the temporal s…”
BackgroundIUPHAR review: Navigating the role of preclinical models in pain research
Karimi, S. A., Zahra, F. T., & Martin, L. J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107073 · Cited by 38
Electrochemical and biosensor techniques to monitor neurotransmitter changes with depression
Dunham, K. E., & Venton, B. J. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05136-9 · Cited by 34
“In addition to glutamate, ketamine may also have effects on serotonin receptors and SERT, but the evidence is less clear [33, 87].”
BackgroundMethodResultInfluentialGu, Y., Zhang, N., Zhu, S., Lu, S., Jiang, H., & Zhou, H. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174939 · Cited by 31
Zheng, Y., & Xu, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646740 · Cited by 35
Brain Plasma Membrane Monoamine Transporter in Health and Disease
Vieira, L. S., & Wang, J. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_446 · Cited by 26
The Ketamine Antidepressant Story: New Insights
Alshammari, T. K. (2020) · Molecules · doi:10.3390/molecules25235777 · Cited by 23
“Of note, high-speed chronoamperometry performed during in vivo studies of the hippocampal CA3 indicated that ketamine prevented the clearance of serotonin in wild-type mice, but failed to achieve this in SERT or PMAT transgenic mice [87].”
BackgroundBönisch, H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_516 · Cited by 22
SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila
Dunham, K. E., & Venton, B. J. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15658 · Cited by 23
“Previously, FSCV and other electrochemical techniques have been used to understand serotonin dynamics in mammals (Bowman et al., 2020; Kile et al., 2010; Wood et al., 2014).”
BackgroundMethodRajkumar, R. P. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.621853 · Cited by 22
Tan, T., Xu, Z., Gao, C., Shen, T., Li, L., Chen, Z., Chen, L., Xu, M., Chen, B., Liu, J., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03860-z · Cited by 30
Organic Cation Transporters in Psychiatric Disorders
Daws, L. C. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_473 · Cited by 18
Self-citationHolik, A., Schweiger, K., Stoeger, V., Lieder, B., Reiner, A., Zopun, M., Hoi, J. K., Kretschy, N., Somoza, M. M., Kriwanek, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115881 · Cited by 12
Zheng, J., Wang, H., Wu, W., Wang, L., Qin, M., Zhu, L., Liu, Z., Chen, Y., & Yu, Y. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03408-4 · Cited by 12
“Notably, recent research has shown that the knockout of Slc29a4 or Sert diminished the inhibitory effect of ketamine on serotonin clearance in mice, resulting in the loss of ketamine’s antidepressant-like effects [87].”
Lamontagne, S. J., Ballard, E. D., & Zarate, C. A. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100450 · Cited by 12
Organic cation transporters in psychiatric and substance use disorders
Honan, L. E., Fraser‐Spears, R., & Daws, L. C. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108574 · Cited by 10
Self-citationDunham, K. E., Khaled, K. H., Weizman, L., & Venton, B. J. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16070 · Cited by 9
“Electrochemical techniques have been used to measure rapid serotonin changes with SSRIs and psychedelics in Drosophila and mice (Bowman et al., 2020 ; Dunham & Venton, 2020 , 2022 ; Hashemi et al., 2009 , 2012 ; Saylor et al., 2019 ; Wood et al., 2014 ).”
BackgroundMethodInfluentialChen, C., Zhou, N., & Hou, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251339378 · Cited by 9
“61 To reduce adverse effects, subanesthetic doses of ketamine are commonly administered for analgesia, combined with other agents such as benzodiazepines or anticholinergic drugs for anesthesia.”
Weber, B. L., Beaver, J. N., & Gilman, T. L. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13810 · Cited by 6
“…some perceptions of uptake 2 monoamine transporters merely serving as redundancies to uptake 1 monoamine transporters, the articles covered in this mini review demonstrate that the former class of transporters does contribute meaningfully to monoamine signalling under baseline conditions (Table 1).”
BackgroundInhibition of SERT and NMDAR synergistically confers rapid antidepressant effects of ketamine
Luo, H., Chen, M., Ning, Y., Ren, L., Lu, Y., Sun, J., Zhu, X., Ran, M., Guo, J., Lu, C., et al. (2025) · National Science Review · doi:10.1093/nsr/nwaf367 · Cited by 5
“Ketamine fails to elicit rapid and sustained antidepressant effects in either SERT knockout mice or mice with 5-HT depletion [25 ,50 ]; however, the precise mechanisms by which the serotonergic system contributes to ketamine’s antidepressant effects remain elusive.”
Advances in Real-Time Electrochemical Monitoring of Neurotransmitter Dynamics in Drosophila
Meng, L., Liu, W., Niu, Y., Lv, X., Jin, T., Wang, G., Sun, Z., Wang, Y.-M., Yang, Y., & Wang, Y. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00960 · Cited by 2
Nepton, A., Farahani, H., Williams, M. T., Booij, L., & Faber, S. C. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00343 · Cited by 2
Coutellier, L. D., Musazzi, L., & Pavlovic, Z. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_4 · Cited by 2
Deshmukh, S. S., & Kale, A. (2023) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-14347 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations
Ciarimboli, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020732 · Cited by 1
“investigated whether this effect of ketamine is due to an influence on extracellular serotonin concentration [6].”
BackgroundKetamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 2
Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations
Ciarimboli, G. (2021) · MDPI eBooks · doi:10.3390/books978-3-0365-0563-3
Nucleotide Contribution to the Functioning of SERT, Na /K ATPase and GPCR Proteins
Williams, W. R. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.125006
How Electrochemical Measurements in the Brain Have Shaped Our Understanding of Depression
Batey, L., Baumberger, B., Prieto, P., & Hashemi, P. (2026) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-052225-082205
Samina, M. C. F., Stanciu, M., Merkelijn, T., Garcia, L. P., Hanswijk, S. I., Witteveen, J. S., Alenina, N. V., Bäder, M., Homberg, J. R., & Kolk, S. M. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00382
Metadata
- Authors
- Bowman, M. A., Vitela, M., Clarke, K. M., Koek, W., & Daws, L. C.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Daws, Lynette C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-10-14
- Volume
- 21
- Issue
- 20
- Pages
- 7581
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7589995
- OpenAlex
- W3092969389
- Cited by
- 33
- References
- 79
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 10 · 2020: 1
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R01MH093320, R01MH106978)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, antidepressant mechanism, serotonin transporter, plasma membrane monoamine transporter, serotonin clearance, extracellular serotonin, major depressive disorder, NMDA receptor antagonists, hippocampal CA3, forced swim test
- MeSH terms
- Animals, Antidepressive Agents, Ketamine, Male, Mice, Inbred C57BL, Nucleus Accumbens, Serotonin, Equilibrative Nucleoside Transport Proteins, Serotonin Plasma Membrane Transport Proteins, Mice, CA3 Region, Hippocampal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.